Strategic Diagnostics Announces Progress in Advancing Clinical Biomarker Discovery
Successful Application of Technology in Cancer Biomarker Identification at M.D. Anderson Cancer Center
Strategic Diagnostics Inc. (Nasdaq:SDIX) – today announced progress in collaborating with the Kleberg Center for Molecular Markers at The University of Texas M. D. Anderson Cancer Center. The center is currently testing SDI’s Genomic Antibody Technology™ (GAT) platform in oncology biomarker discovery research.
SDI’s sequence-based GAT platform triggers the immune system of the host to produce an antibody against a native protein. Through internal and third party analysis, these antibodies have demonstrated superior performance in the recognition and targeting of native protein targets in experimental models and clinical samples as compared to reagents made with traditional methods.
Participating in a collaborative study, independent researchers at M. D. Anderson have now used SDI’s growing library of GAT antibodies to screen hundreds of clinical cancer biopsy samples in a high throughput system to analyze the differential presence of proteins in the tissue samples. The individual protein signature of these samples created with SDI’s reagents allows further research into the clinical significance of the findings. The correlation of the data with the corresponding disease state represented by the samples is focused on yielding new tools to improve diagnostic, prognostic, and patient monitoring decisions.
Matthew H. Knight, SDI’s President and Chief Executive Officer, stated, “As demonstrated in the performance of our antibodies in the M. D. Anderson cancer screens, the fundamental advantages of Genomic Antibody Technology™ clearly benefits the pace, scope, and precision of modern biomarker discovery. We are encouraged by these results and are confident the next phase of the offering’s commercial expansion will further enable our scientists, collaborators and customers in their efforts toward advancing the discovery and understanding of significant protein patterns in human health.”
Strategic Diagnostics offers custom service access to the Genomic Antibody Technology™ platform in polyclonal and monoclonal products as well as a rapidly expanding portfolio of Catalog Reagents targeting cancer markers. These offerings complement SDI’s breadth of traditional antibody development/production services and clinical diagnostic products.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable “return on investment” by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company’s established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
Strategic Diagnostics Inc.
Stan Fronczkowski
Chief Financial Officer
302-456-6789
www.sdix.com
or
Investor Contact:
Hayden Communications
Brett Maas
646-536-7331
brett@haydenir.com
Source: Business Wire (October 25, 2007 - 7:58 AM EDT)
News by QuoteMedia
www.quotemedia.com
AI
